Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study
Summary
On April 2, Beam Therapeutics Inc. (NASDAQ:BEAM) released results from its Phase 1/2 BEACON study for ristoglogene autogetemcel.
Description
On April 2, Beam Therapeutics Inc. (NASDAQ:BEAM) released results from its Phase 1/2 BEACON study for ristoglogene autogetemcel.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source